

AKORN INC  
Form 8-K  
August 12, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event Reported): August 12, 2014

**Akorn, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Louisiana**  
(State or Other Jurisdiction of Incorporation)

**001-32360**  
(Commission File Number)

**72-0717400**  
(I.R.S. Employer Identification Number)

**1925 W. Field Court, Suite 300**  
**Lake Forest, Illinois 60045**  
(Address of principal executive offices)

**(847) 279-6100**  
(Registrant's telephone number, including area code)

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events.**

On August 12, 2014, Akorn, Inc. ("Akorn", or the "Company") issued a press release announcing that the Company has completed its acquisition of VPI Holdings Corp., the parent company of VersaPharm Incorporated ("VersaPharm"). Attached as Exhibit 99.1 and incorporated by reference into this Item 8.01 is a copy of the press release furnished as Exhibit 99.1 to this report.

The information in this Item 8.01, including exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. See attached exhibit index.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 12, 2014

Akorn, Inc.

By: /s/ TIMOTHY A. DICK  
Timothy A. Dick  
Chief Financial Officer

---

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated August 12, 2014, issued by Akorn, Inc. announcing the completion of the acquisition of VPI Holdings Corp., the parent Company of VersaPharm Incorporated.